In recent years, we have identified many molecular pathways that influence the activity of anti-CD20 antibodies (Pyrzynska et al. 2018, Bobrowicz et al. 2017, Bojarczuk et al. 2014, Dwojak et al. 2015, Winiarska et al. 2012 and 2014).

Currently, our research focuses on the characterization of phenotypic changes occurring in cells with acquired resistance to monoclonal antibodies, in particular to rituximab. Using rituximab-resistant lymphoma cell lines, we showed that a decrease in CD20 is associated with reduced expression of CD37 - a protein that is currently being explored as a therapeutic target for immunotherapy, i.e. monoclonal antibodies, antibody-drug conjugates and CAR-T cells (Bobrowicz et al. doi .org/10.1101/2023.12.06.570441). We are also searching for other significant changes related to antibody resistance in order to propose novel strategies that sensitize cancer cells to the subsequent lines of treatment.